RECRUITING

Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to test the safety of the drug Angiotensin (1-7) and learn whether it works well as a treatment in people who have suffered a moderate to severe traumatic brain injury (TBI). The main questions this trial aims to answer are: * Is Angiotensin (1-7) safe? * Does Angiotensin (1-7) improve mental functioning and reduce physical signs of brain damage in people who have suffered a moderate to severe TBI? Participants will: * Complete 21 days of study treatment consisting of a once-daily injection. * Provide blood samples. * Undergo two magnetic resonance imaging (MRI) scans of the brain. * Complete specific tasks and questionnaires that allow researchers to evaluate the participant's brain and psychological functioning. Researchers will compare three groups: two groups that receive different doses of Angiotensin (1-7) and one group that receives a look-alike treatment with no active drug. This will allow researchers to see if the drug has any negative effects and whether it improves mental functioning and physical signs of brain damage after a TBI.

Official Title

A Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of Angiotensin (1-7) in Persons With Moderate to Severe Traumatic Brain Injury (TBI)

Quick Facts

Study Start:2024-05-28
Study Completion:2027-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06282965

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Participant or representative willing to provide informed consent.
  2. * Age 18 years or older at time of enrollment.
  3. * Traumatically induced head injury resulting from insult to head from an external force.
  4. * Clinical diagnosis of acute intracranial lesion based on neuroradiologist report. CT scan and report must be available.
  5. * Moderate or severe traumatic brain injury (TBI) defined as Glasgow Coma Scale (GCS) score on trauma presentation of 12 or less. In general: Moderate TBI will be defined as loss of consciousness between 30 minutes and 24 hours and GCS between 9 and 12. Severe TBI will be defined as loss of consciousness \> 24 hours and GCS ≤ 9.
  6. * Enrollment within 48 hours of TBI.
  1. * Time of injury cannot be determined.
  2. * Neurosurgery within the last 30 days.
  3. * History of neurodegenerative disease or disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors that would impact cognitive testing.
  4. * Contraindication to having an MRI.
  5. * Pregnant or lactating female.
  6. * Female of childbearing potential or sexually active male who is not willing to use an acceptable method of birth control for the treatment period and 7 days after the last dose of the study drug.
  7. * Participation in another clinical study involving investigational product within 30 days prior to study enrollment.
  8. * If in the opinion of the investigator, candidate is unsuitable for participation in the study.

Contacts and Locations

Study Contact

Clinical Research Coordinator
CONTACT
(520) 237-6845
traumaresearch@arizona.edu

Principal Investigator

Bellal Joseph, MD
PRINCIPAL_INVESTIGATOR
University of Arizona

Study Locations (Sites)

University of Arizona
Tucson, Arizona, 85724
United States

Collaborators and Investigators

Sponsor: University of Arizona

  • Bellal Joseph, MD, PRINCIPAL_INVESTIGATOR, University of Arizona

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-05-28
Study Completion Date2027-09

Study Record Updates

Study Start Date2024-05-28
Study Completion Date2027-09

Terms related to this study

Keywords Provided by Researchers

  • renin angiotensin system
  • cognition

Additional Relevant MeSH Terms

  • Traumatic Brain Injury